Public deck

Eli Lilly: obesity-drug scale is now a manufacturing and cash-conversion test

Eli Lilly reported FY2025 revenue of $65.2 billion and 2026 Q1 revenue of $19.8 billion. The thesis depends on tirzepatide demand, manufacturing capacity, pipeline reinvestment and cash conversion.